Sezaki T
Rinsho Ketsueki. 1989 Aug;30(8):1216-9.
Between 1971 and 1985, 133 patients were diagnosed as symptomatic multiple myeloma. Recently the number and percentage of patients, who were older (70 years old) and type of diffuse proliferation, were remarkably increased. In 132 previously untreated patients who received chemotherapy, the 50% Survival time was 32 months; thirty-nine (29%) survived more than five years after treatment and 4 of them (3%) survived more than ten years. Among the prognostic factors related to survival time, serum albumin level, M-protein type, bone marrow plasma cell (%), clinical stage and classification according to tumor distribution were considered to be significantly important. Clinical responses were evaluated in 120 patients who received combination chemotherapy for at least 3 months. A 50% or more reduction of M-protein was obtained in 58% and a marked improvement in bone pain or motor-disturbance was found in 54%. Overall response rate evaluated by the effects of both objective and subjective symptoms was 43%. New criteria for response defined by the level of serum albumin and M-protein after treatment were proposed.
1971年至1985年间，133例患者被诊断为有症状的多发性骨髓瘤。最近，年龄较大（70岁）的患者数量和比例以及弥漫性增殖类型显著增加。在132例接受化疗的初治患者中，50%生存期为32个月；39例（29%）治疗后存活超过5年，其中4例（3%）存活超过10年。在与生存时间相关的预后因素中，血清白蛋白水平、M蛋白类型、骨髓浆细胞（%）、临床分期以及根据肿瘤分布的分类被认为具有显著重要性。对120例接受联合化疗至少3个月的患者进行了临床反应评估。58%的患者M蛋白降低了50%或更多，54%的患者骨痛或运动障碍有明显改善。根据客观和主观症状的效果评估的总反应率为43%。提出了根据治疗后血清白蛋白和M蛋白水平定义的新反应标准。
